Scientia has leveraged its novel microfabrication technology platform to launch a portfolio of highly differentiated neurovascular products used at leading comprehensive and primary stroke centers.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/28/21 | $50,000,000 | Growth |
Vivo Capital | undisclosed |
